Literature DB >> 8100491

Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases.

M Volm1, P Drings, W Wodrich, G van Kaick.   

Abstract

In the current study the relationship between the incidence of metastatic spread and expression (at the protein level) of various proto-oncogenes was investigated in 217 human non-small cell lung carcinomas. Tumors with an overexpression of proteins encoded by the oncogenes c-jun and c-myc showed a significantly increased formation of metastases (c-jun: P = 0.008; c-myc: P = 0.018). No significant correlations were found between the expression of the c-fos, c-erbB1, c-neu and c-ras products and metastatic spread.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100491     DOI: 10.1007/bf00058052

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  22 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  Ploidy of primary and metastatic human tumors.

Authors:  G RABOTTI
Journal:  Nature       Date:  1959-05-02       Impact factor: 49.962

3.  High invasiveness associated with augmentation of motility in a fos-transferred highly metastatic rat 3Y1 cell line.

Authors:  S Taniguchi; M Tatsuka; K Nakamatsu; M Inoue; H Sadano; H Okazaki; H Iwamoto; T Baba
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

4.  Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4.

Authors:  M Volm; M Bak; T Efferth; B Lathan; J Mattern
Journal:  Anticancer Res       Date:  1988 Jul-Aug       Impact factor: 2.480

5.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

6.  ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.

Authors:  K Sugio; T Ishida; H Yokoyama; T Inoue; K Sugimachi; T Sasazuki
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

7.  Comparison of cellular protooncogene activation and transformation-related activity of human melanocytes and metastatic melanoma.

Authors:  Z Husain; G B FitzGerald; M M Wick
Journal:  J Invest Dermatol       Date:  1990-11       Impact factor: 8.551

Review 8.  The pathogenesis of cancer metastasis.

Authors:  G Poste; I J Fidler
Journal:  Nature       Date:  1980-01-10       Impact factor: 49.962

9.  Detection of fos protein during osteogenesis by monoclonal antibodies.

Authors:  P De Togni; H Niman; V Raymond; P Sawchenko; I M Verma
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

10.  NIH3T3 transfectant containing human K-ras oncogene shows enhanced metastatic activity after in vivo tumor growth or co-culture with fibroblasts.

Authors:  Y Takiguchi; Y Takahashi; T Kuriyama; T Miyamoto
Journal:  Clin Exp Metastasis       Date:  1992-09       Impact factor: 5.150

View more
  8 in total

Review 1.  Cancer models in Caenorhabditis elegans.

Authors:  Natalia V Kirienko; Kumaran Mani; David S Fay
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

2.  Microvessel density, expression of proto-oncogenes, resistance-related proteins and incidence of metastases in primary ovarian carcinomas.

Authors:  M Volm; R Koomagi; M Kaufmann; J Mattern; G Stammler
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

3.  MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.

Authors:  Antonella Flacco; Vienna Ludovini; Fortunato Bianconi; Mark Ragusa; Guido Bellezza; Francesca R Tofanetti; Lorenza Pistola; Annamaria Siggillino; Jacopo Vannucci; Lucio Cagini; Angelo Sidoni; Francesco Puma; Marileila Varella-Garcia; Lucio Crinò
Journal:  Am J Clin Oncol       Date:  2015-04       Impact factor: 2.339

4.  A dominant-negative c-jun mutant inhibits lung carcinogenesis in mice.

Authors:  Jay W Tichelaar; Ying Yan; Qing Tan; Yian Wang; Richard D Estensen; Matthew R Young; Nancy H Colburn; Hulian Yin; Colleen Goodin; Marshall W Anderson; Ming You
Journal:  Cancer Prev Res (Phila)       Date:  2010-08-17

5.  Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases.

Authors:  M Volm; G van Kaick; J Mattern
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

Review 6.  Altered glutamine metabolism and therapeutic opportunities for lung cancer.

Authors:  Amr Mohamed; Xingming Deng; Fadlo R Khuri; Taofeek K Owonikoko
Journal:  Clin Lung Cancer       Date:  2013-11-13       Impact factor: 4.785

7.  Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression.

Authors:  T L Walker; J D White; W J Esdale; M A Burton; E E DeCruz
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

8.  In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.

Authors:  Caitlin L Grzeskowiak; Samrat T Kundu; Xiulei Mo; Andrei A Ivanov; Oksana Zagorodna; Hengyu Lu; Richard H Chapple; Yiu Huen Tsang; Daniela Moreno; Maribel Mosqueda; Karina Eterovic; Jared J Fradette; Sumreen Ahmad; Fengju Chen; Zechen Chong; Ken Chen; Chad J Creighton; Haian Fu; Gordon B Mills; Don L Gibbons; Kenneth L Scott
Journal:  Nat Commun       Date:  2018-07-16       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.